Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions

Twist Bioscience Corporation (NASDAQ:TWST) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The firm has expanded its relationship with Element Biosciences to produce end-to-end Next Generation Sequencing (NGS) solutions.

Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions.

A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug discovery.

Twist Bioscience Corporation (NASDAQ:TWST)’s library prep and target enrichment workflows are now integrated with Element’s AVITI™ devices and Trinity™ flowcells. Twist will be the only supplier of the new Trinity kits for the AVITI platform as a result of the deal. Both businesses will collaborate on commercial efforts to increase customer access to high-performance NGS technologies.

The expanded relationship builds on past success, including Twist Bioscience Corporation (NASDAQ:TWST)’s Trinity solution for one-hour quick hybridization. The partnership will improve workflows for agbio, genomics, and clinical research by streamlining hybrid capture both off and on sequencers, according to Twist CEO Emily Leproust.

Element Biosciences CEO Molly He highlighted that the combination of Twist Bioscience Corporation (NASDAQ:TWST)’s prep capabilities and Trinity’s focused sequencing is essential to advancing science. The partnership will provide researchers with platform flexibility, uniformity, and quality by extending NGS capabilities beyond exome sequencing.

While we acknowledge the potential of TWST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.